Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 9/2007

01-09-2007 | Case Report

Mixed connective tissue disease: a case with scleroderma renal crisis following abortion

Authors: Mehmet Celikbilek, Rengin Elsurer, Baris Afsar, Handan B. Ozdemir, Siren Sezer, Nurhan F. Ozdemir

Published in: Clinical Rheumatology | Issue 9/2007

Login to get access

Abstract

The term mixed connective tissue disease (MCTD) has been applied to a particular subset of patients with overlapping clinical features of systemic sclerosis, systemic lupus erythematosus, and polymyositis. Immune response to U1-ribonucleoprotein is the defining serological feature of MCTD. There are different organ and system involvements in MCTD including the heart, lung, kidney, muscle, joints, gastrointestinal, and hematologic involvements. Reports describing pregnancies in patients with MCTD are rare, and the results have been contradictory: a high risk of fetal loss and of disease exacerbation or no influence on fetus or mother. In MCTD, simultaneous pulmonary and renal involvement is very rare. In this paper, we report a case of MCTD with pulmonary involvement that developed scleroderma renal crisis after an abortion.
Literature
1.
2.
Takeda Y, Wang GS, Wang RJ et al (1989) Enzyme-linked immunosorbent assay using isolated (U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical significance of autoantibodies to these polypeptides. Clin Immunol Immunopathol 50:213–230PubMedCrossRef
3.
Bennett RM, O’Connell DJ (1980) Mixed connective tissue disease: a clinicopathologic study of 20 cases. Semin Arthritis Rheum 10:25–51PubMedCrossRef
4.
Kaufman RL, Kitridou RC (1982) Pregnancy in mixed connective tissue disease: comparison with systemic lupus erythematosus. J Rheumatol 9:549–555PubMed
5.
Lundberg I, Hedfors E (1991) Pregnancy outcome in patients with high titer anti-RNP antibodies. A retrospective study of 40 pregnancies. J Rheumatol 18:359–362PubMed
6.
Snyder JM, De Masi AD, Belsky DH (1985) Mixed connective tissue disease in pregnancy: report of a case. J Am Osteopath Assoc 85:33–36PubMed
7.
Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC (1999) Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 42:899–909PubMedCrossRef
8.
Satoh K, Imai H, Yasuda T, Wakui H, Miura AB, Nakamoto Y (1994) Sclerodermatous renal crisis in a patient with mixed connective tissue disease. Am J Kidney Dis 24:215–218PubMed
9.
McHugh NJ, Reilly PA, McHugh LA (1989) Pregnancy outcome and autoantibodies in connective tissue disease. J Rheumatol 16:42–46PubMed
10.
Grennan DM, McCormick JN, Wojtacha D, Carty M, Behan W (1978) Immunological studies of the placenta in systemic lupus erythematosus. Ann Rheum Dis 37:129–134PubMedCrossRef
11.
Horita Y, Tsunoda S, Inenaga T et al (2001) Pregnancy outcome in nephrotic syndrome with mixed connective tissue disease. Nephron 89:354–356PubMedCrossRef
12.
Ackerman J, Gonzalez EF, Gilbert-Barness E (1999) Immunological studies of the placenta in maternal connective tissue disease. Pediatr Dev Pathol 2:19–24PubMedCrossRef
13.
Vancheeswaran R, Magoulas T, Efrat G et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838–1844PubMed
Metadata
Title
Mixed connective tissue disease: a case with scleroderma renal crisis following abortion
Authors
Mehmet Celikbilek
Rengin Elsurer
Baris Afsar
Handan B. Ozdemir
Siren Sezer
Nurhan F. Ozdemir
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0442-8

Other articles of this Issue 9/2007

Clinical Rheumatology 9/2007 Go to the issue

Letter to the Editor

Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis

Original Article

Evaluation of pulmonary function and bicycle ergometry tests in patients with Behçet’s disease

Case Report

The expanded clinical spectrum of familial Mediterranean fever

Original Article

Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome

Original Article

No effects of adalimumab therapy on the activation of NF-κB in lymphocytes from patients with severe rheumatoid arthritis

Original Article

Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits